CLAIMS

1. The use of trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of primary negative symptoms of schizophrenia.

2. The use according to claim 1, wherein the trans-4-{2-[-4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarnamoyl-cyclohexylamine is in the form of trans-4-{2-[-4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarnamoyl-cyclohexylamine hydrochloride.

3. The use of trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of predominantly negative symptoms in schizophrenia.

4. The use according to claim 3, wherein the trans-4-{2-[-4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarnamoyl-cyclohexylamine is in the form of trans-4-{2-[-4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarnamoyl-cyclohexylamine hydrochloride.